Free Trial
NASDAQ:PALI

Palisade Bio (PALI) Stock Price, News & Analysis

Palisade Bio logo
$1.67 -0.10 (-5.65%)
(As of 12/27/2024 05:45 PM ET)

About Palisade Bio Stock (NASDAQ:PALI)

Key Stats

Today's Range
$1.63
$1.77
50-Day Range
$1.40
$3.91
52-Week Range
$1.38
$22.35
Volume
149,263 shs
Average Volume
661,790 shs
Market Capitalization
$2.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Buy

Company Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Palisade Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
43rd Percentile Overall Score

PALI MarketRank™: 

Palisade Bio scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Palisade Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Palisade Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Palisade Bio are expected to grow in the coming year, from ($12.43) to ($2.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Palisade Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Palisade Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Palisade Bio has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    67.65% of the float of Palisade Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Palisade Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Palisade Bio has recently increased by 1,610.04%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Palisade Bio does not currently pay a dividend.

  • Dividend Growth

    Palisade Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    67.65% of the float of Palisade Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Palisade Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Palisade Bio has recently increased by 1,610.04%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Palisade Bio has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Palisade Bio this week, compared to 2 articles on an average week.
  • Search Interest

    6 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Palisade Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.28% of the stock of Palisade Bio is held by insiders.

  • Percentage Held by Institutions

    Only 11.79% of the stock of Palisade Bio is held by institutions.

  • Read more about Palisade Bio's insider trading history.
Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

PALI Stock News Headlines

Mysterious drone activity triggers massive 1,366% surge
If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.
See More Headlines

PALI Stock Analysis - Frequently Asked Questions

Palisade Bio's stock was trading at $8.85 at the beginning of the year. Since then, PALI stock has decreased by 81.1% and is now trading at $1.67.
View the best growth stocks for 2024 here
.

Palisade Bio, Inc. (NASDAQ:PALI) posted its earnings results on Tuesday, November, 12th. The company reported ($2.32) EPS for the quarter, beating analysts' consensus estimates of ($3.35) by $1.03.

Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Top institutional shareholders of Palisade Bio include JPMorgan Chase & Co. (0.54%). Insiders that own company stock include John David Finley, Thomas Hallam, Donald Allen Williams, Michael John Dawson and Robert J Trenschel.
View institutional ownership trends
.

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Onconova Therapeutics (ONTX), Sesen Bio (SESN), Iterum Therapeutics (ITRM), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA).

Company Calendar

Last Earnings
11/12/2024
Today
12/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PALI
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$38.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+1,277.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-12,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$18.29 per share

Miscellaneous

Free Float
1,285,000
Market Cap
$2.53 million
Optionable
Not Optionable
Beta
1.39
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:PALI) was last updated on 12/28/2024 by MarketBeat.com Staff
From Our Partners